N@N

OBAGI MEDICAL PRODUCTS INC (NASDAQ:OMPI), Up By 6.14% ($0.71) After BUYINS.NET SqueezeTrigger Report Released on Wednesday, Mar

^{Published on 2011-03-11 09:01:47 - WOPRAI}
 

March 11, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Wednesday, March 9th 2011 at 08:16:00 PST stating that OBAGI MEDICAL PRODUCTS INC (NASDAQ:OMPI) was expected to be Up After it crossed above its SqueezeTrigger Price of 11.494 on Wednesday, March 9th 2011. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=ompi&id=152496

From August 2009 to February 2011, an aggregate amount of 8477963 shares of OMPI have been shorted for a total dollar value of $93257593. The OMPI SqueezeTrigger price of $11.494 is the volume weighted average price that all shorts are short in shares of OMPI. There is still approximately $7578669.00 of potential short covering in shares of OMPI.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

OBAGI MEDICAL PRODUCTS INC (NASDAQ:OMPI) - Obagi Medical Products, Inc., a specialty pharmaceutical company, develops and markets topical aesthetic and therapeutic prescription skin care systems in the United States and internationally. It offers Obagi Nu-Derm System, which includes prescription and OTC drugs that are used for the treatment of fine lines, wrinkles, acne, photo-damage, hyperpigmentation, melasma, laxity, and skin sallowness; Obagi Condition and Enhance Systems that are used before and after surgical and non-surgical cosmetic procedures; Obagi-C Rx System, a combination of prescription, OTC drugs, and adjunctive cosmetic skin care products to treat skin conditions resulting from sun damage and the oxidative damage of free radicals; and Obagi Professional-C products, a line of proprietary, non-prescription products, which consist of vitamin C serums used to reduce the appearance of damage to the skin caused by ultraviolet radiation and other environmental influences. The company also provides ELASTIderm Eye and Decolletage, which increase the elasticity and skin tone of eyes, face, neckline, and chest; CLENZIderm M.D. Systems used for the treatment of acne; Obagi Rosaclear System used for the treatment of rosacea; Tretinoin used for the treatment of acne; Refissa used for the treatment of fine facial lines, hyperpigmentation, and tactile roughness; Metronidazole, an antibiotic used for the treatment of rosacea in the United States; and Obagi Blue Peel System used for the treatment of fine lines, wrinkles, and hyperpigmentation. In addition, it licenses certain non-prescription product concepts to Japanese based pharmaceutical companies for sale in Japan under the Obagi trademark. Obagi Medical Products, Inc. sells its products through own domestic sales force and foreign distributors to dermatologists, plastic surgeons, and other physicians that are focused on aesthetic and therapeutic skin care. The company was founded in 1988 and is headquartered in Long Beach, California.

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net